JonesTrading has started following Beam Therapeutics and thinks it's a good buy, setting a target price of $35.

Nov 5, 2026, 2:45 PM ETOpinionRead the original at moomoo.com

Good for BEAM

JonesTrading started coverage of Beam with a Buy rating and a $35 target. This supports a more positive view, but the report brings no new trial or business results.

BEAM · Beam Therapeutics Inc.

AI read · Good for BEAM

The AI's read

That gives investors one outside firm's favorable view of Beam's prospects. It may draw attention, but the report brings no new trial or business results, so the support comes from the analyst's opinion.

Get alerts for BEAM

Follow Beam Therapeutics Inc. (BEAM) free. When we publish a story about it, you get the plain-English explanation as an alert.

Get alerts for BEAM

Free on the App Store and Google Play, or on the web.